CCO Oncology Podcast

185 Épisodes

1. Experts Answer Questions on the Management of Patients With T-Cell Lymphomas

   Publié: 17/02/2023
2. Experts Answer Questions on Personalized Management of Patients With Myelodysplastic Syndromes

   Publié: 17/02/2023
3. Individualizing Care for Patients With Triple-Negative Breast Cancer

   Publié: 18/01/2023
4. Contemporary Approaches to Treating Polycythemia Vera: A Conversation Between Experts

   Publié: 11/01/2023
5. HCC Surveillance: Challenges and Opportunities

   Publié: 03/01/2023
6. A Patient’s Perspective on Effective Communication With the Healthcare Team: My Journey With High-Risk HR-Positive/HER2-Negative Early Breast Cancer

   Publié: 13/12/2022
7. The Transgender Cancer Experience: A Conversation Between an Oncologist and a Transmasculine Individual on Navigating the Healthcare System

   Publié: 29/11/2022
8. Expert Thoughts on Studies of Interest Presented at the 2022 ESGO Annual Meeting on Gynecologic Cancers

   Publié: 29/11/2022
9. Evolving Role of BTK Inhibitors in CLL: Experts Answer Your Questions

   Publié: 09/11/2022
10. New Evidence With BTK Inhibitor Therapy in CLL and MCL From the SOHO 2022 Annual Meeting

    Publié: 28/10/2022
11. Relapsed/Refractory Myeloma: Navigating the Complex Treatment Landscape

    Publié: 24/10/2022
12. Expert Thoughts on Key Trials of Interest for Ovarian and Cervical Cancer at the IGCS 2022 Annual Global Meeting

    Publié: 24/10/2022
13. Expert Insights on Key Updates From the 2022 ESMO Congress on PARP Inhibitors in Ovarian Cancer

    Publié: 04/10/2022
14. Managing EGFR-Mutated Non-Small-Cell Lung Cancer in Today’s Clinic: Expert Answers to Frequently Asked Questions

    Publié: 28/09/2022
15. New Evidence With BTK Inhibitor Therapy in CLL and MCL From the Pan Pacific Lymphoma Conference 2022

    Publié: 30/08/2022
16. Experts Discuss Challenges in Advanced Hepatocellular Carcinoma Management

    Publié: 22/08/2022
17. HER2-Positive Breast Cancer: Current Approaches for Quality Care

    Publié: 28/07/2022
18. New Evidence With BTK Inhibitor Therapy in CLL and MCL From EHA 2022

    Publié: 21/07/2022
19. New Evidence With BTK Inhibitor Therapy in CLL and MCL From ASCO 2022

    Publié: 06/07/2022
20. Expert Insights on New Data From ASCO 2022 Informing Treatment for Endometrial, Ovarian, and Cervical Cancers

    Publié: 30/06/2022